566 related articles for article (PubMed ID: 32125907)
21. Antisense Oligonucleotides for the Study and Treatment of ALS.
Boros BD; Schoch KM; Kreple CJ; Miller TM
Neurotherapeutics; 2022 Jul; 19(4):1145-1158. PubMed ID: 35653060
[TBL] [Abstract][Full Text] [Related]
22. [Prion-like Properties of Misfolded Cu/Zn-superoxide Dismutase in Amyotrophic Lateral Sclerosis: Update and Perspectives].
Tokuda E; Marklund SL; Furukawa Y
Yakugaku Zasshi; 2019; 139(7):1015-1019. PubMed ID: 31257248
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs.
Wang L; Yi F; Fu L; Yang J; Wang S; Wang Z; Suzuki K; Sun L; Xu X; Yu Y; Qiao J; Belmonte JCI; Yang Z; Yuan Y; Qu J; Liu GH
Protein Cell; 2017 May; 8(5):365-378. PubMed ID: 28401346
[TBL] [Abstract][Full Text] [Related]
24. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model.
Biferi MG; Cohen-Tannoudji M; Cappelletto A; Giroux B; Roda M; Astord S; Marais T; Bos C; Voit T; Ferry A; Barkats M
Mol Ther; 2017 Sep; 25(9):2038-2052. PubMed ID: 28663100
[TBL] [Abstract][Full Text] [Related]
25. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis?
Kabashi E; Valdmanis PN; Dion P; Rouleau GA
Ann Neurol; 2007 Dec; 62(6):553-9. PubMed ID: 18074357
[TBL] [Abstract][Full Text] [Related]
26. Variability in SOD1-associated amyotrophic lateral sclerosis: geographic patterns, clinical heterogeneity, molecular alterations, and therapeutic implications.
Huang M; Liu YU; Yao X; Qin D; Su H
Transl Neurodegener; 2024 May; 13(1):28. PubMed ID: 38811997
[TBL] [Abstract][Full Text] [Related]
27. [Gene-specific treatment approaches in amyotrophic lateral sclerosis in the present and future].
Brenner D; Freischmidt A; Ludolph AC; Weishaupt JH
Nervenarzt; 2020 Apr; 91(4):287-293. PubMed ID: 32076756
[TBL] [Abstract][Full Text] [Related]
28. Novel chemical inhibitor against SOD1 misfolding and aggregation protects neuron-loss and ameliorates disease symptoms in ALS mouse model.
Woo TG; Yoon MH; Kang SM; Park S; Cho JH; Hwang YJ; Ahn J; Jang H; Shin YJ; Jung EM; Ha NC; Kim BH; Kwon Y; Park BJ
Commun Biol; 2021 Dec; 4(1):1397. PubMed ID: 34912047
[TBL] [Abstract][Full Text] [Related]
29. Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype.
Nizzardo M; Simone C; Rizzo F; Ulzi G; Ramirez A; Rizzuti M; Bordoni A; Bucchia M; Gatti S; Bresolin N; Comi GP; Corti S
Sci Rep; 2016 Feb; 6():21301. PubMed ID: 26878886
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.
Becker LA; Huang B; Bieri G; Ma R; Knowles DA; Jafar-Nejad P; Messing J; Kim HJ; Soriano A; Auburger G; Pulst SM; Taylor JP; Rigo F; Gitler AD
Nature; 2017 Apr; 544(7650):367-371. PubMed ID: 28405022
[TBL] [Abstract][Full Text] [Related]
31. Copper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
Tokuda E; Furukawa Y
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136532
[TBL] [Abstract][Full Text] [Related]
32. SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes.
Bunton-Stasyshyn RK; Saccon RA; Fratta P; Fisher EM
Neuroscientist; 2015 Oct; 21(5):519-29. PubMed ID: 25492944
[TBL] [Abstract][Full Text] [Related]
33. A copper-deficient form of mutant Cu/Zn-superoxide dismutase as an early pathological species in amyotrophic lateral sclerosis.
Tokuda E; Nomura T; Ohara S; Watanabe S; Yamanaka K; Morisaki Y; Misawa H; Furukawa Y
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2119-2130. PubMed ID: 29551730
[TBL] [Abstract][Full Text] [Related]
34. In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model.
Chen YA; Kankel MW; Hana S; Lau SK; Zavodszky MI; McKissick O; Mastrangelo N; Dion J; Wang B; Ferretti D; Koske D; Lehman S; Koszka K; McLaughlin H; Liu M; Marshall E; Fabian AJ; Cullen P; Marsh G; Hamann S; Craft M; Sebalusky J; Arnold HM; Driscoll R; Sheehy A; Luo Y; Manca S; Carlile T; Sun C; Sigrist K; McCampbell A; Henderson CE; Lo SC
Gene Ther; 2023 May; 30(5):443-454. PubMed ID: 36450833
[TBL] [Abstract][Full Text] [Related]
35. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
Jeon GS; Shim YM; Lee DY; Kim JS; Kang M; Ahn SH; Shin JY; Geum D; Hong YH; Sung JJ
Mol Neurobiol; 2019 Mar; 56(3):2007-2021. PubMed ID: 29982983
[TBL] [Abstract][Full Text] [Related]
36. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
[TBL] [Abstract][Full Text] [Related]
37. Superoxide dismutase-1 mutation-related neurotoxicity in familial amyotrophic lateral sclerosis.
Shibata N; Hirano A; Yamamoto T; Kato Y; Kobayashi M
Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Jun; 1(3):143-61. PubMed ID: 11464949
[TBL] [Abstract][Full Text] [Related]
38. Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China.
Hou L; Jiao B; Xiao T; Zhou L; Zhou Z; Du J; Yan X; Wang J; Tang B; Shen L
Sci Rep; 2016 Sep; 6():32478. PubMed ID: 27604643
[TBL] [Abstract][Full Text] [Related]
39. Superoxide Dismutase 1 (SOD1)-Derived Peptide Inhibits Amyloid Aggregation of Familial Amyotrophic Lateral Sclerosis SOD1 Mutants.
Banerjee V; Shani T; Katzman B; Vyazmensky M; Papo N; Israelson A; Engel S
ACS Chem Neurosci; 2016 Nov; 7(11):1595-1606. PubMed ID: 27540759
[TBL] [Abstract][Full Text] [Related]
40. RNA interference and amyotrophic lateral sclerosis.
Rizvanov AA; Gulluoglu S; Yalvaç ME; Palotás A; Islamov RR
Curr Drug Metab; 2011 Sep; 12(7):679-83. PubMed ID: 21740381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
